An updated systematic review and meta-analysis reported that finerenone reduced composite kidney and cardiovascular risks in diabetic kidney disease. The analysis consolidates evidence from prior randomized studies and updates effect estimates on cardiorenal outcomes. For biotech and pharma decision-makers, the updated synthesis strengthens the evidence foundation for positioning finerenone in broader care pathways that incorporate both renal protection and cardiovascular risk reduction. It also sets a bar for next-generation nonsteroidal mineralocorticoid receptor antagonists seeking differentiation on endpoint breadth and magnitude.